<DOC>
	<DOCNO>NCT00002344</DOCNO>
	<brief_summary>To assess dose proportionality azithromycin concentration toleration deliver tablet formulation HIV-infected patient . The need exist assess antibacterial agent azithromycin differ dos HIV-infected population .</brief_summary>
	<brief_title>A Study Azithromycin HIV-Infected Patients</brief_title>
	<detailed_description>The need exist assess antibacterial agent azithromycin differ dos HIV-infected population . Patients randomize receive azithromycin 1 2 dos two-treatment , two-period , cross-over study . Dosing visit separate least 14-day wash-out period .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV seropositivity . CD4 count &lt; = 500 cells/mm3 . NO active AIDS opportunistic infection . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Other active intercurrent illness . Any condition possibly affect drug absorption ( e.g. , ulcer , gastrectomy , HIVassociated enteropathy . Signs symptom severe illness would preclude study participation . Known allergy macrolide antibiotic . Patients follow prior condition exclude : Clinically important change baseline status within 4 week prior study entry . Prior Medication : Excluded : Investigational drug include treatment IND drug within 4 week prior study entry . Known drug alcohol dependence .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 1996</verification_date>
	<keyword>Azithromycin</keyword>
	<keyword>Bacterial Infections</keyword>
</DOC>